Clinical Trial

A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety and immunogenicity of mRNA-1365, an mRNA vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) and mRNA-1345, an mRNA vaccine targeting RSV, in participants aged 5 months to \<24 months.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2023-02-15; most recent amendment 2026-06-23.
Status change: Recruiting → Active, Not Recruiting 2024-08-08
Status change: Active, Not Recruiting → Recruiting 2024-05-20
Status change: Recruiting → Active, Not Recruiting 2024-01-24
Trial Details
NCT Number NCT05743881
Lead Sponsor ModernaTX, Inc.
Conditions Respiratory Syncytial Virus, Human Metapneumovirus
Enrollment 186 participants
Start Date 2023-02-15
Primary Completion 2029-08-31 (estimated)
Study Completion 2029-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-26